Annual Pharma Investment in “eSales,” “eDetailing,” “Virtual Detailing” … Whatever!
Cutting Edge Information recently published its "Pharmaceutical Sales Management" report, which included data on "eDetailing." Ed Silverman, a Wall Street Journal blogger, summarized the...
Pharma Spends What on eSales?
Ed Silverman -- formerly the author of Pharmalot, now a reporter for the Wall Street Journal -- recently published some interesting pharma sales rep...
Why the FDA Approved Zohydro
The opiate Zohydro was approved by the FDA although that decision went against the recommendation of the agency’s own advisory panel, which voted 11...
Red GOP States Addled by Adderall
Express Scripts, which just released a report titled "Turning Attention to ADHD," found that almost one in 10 adolescent boys were taking stimulant medication...
FDA’s “Crimean Referendum” Putsched Aveed Through the Approval Process
The FDA recently approved Endo Pharmaceuticals' testosterone replacement therapy drug Aveed (testosterone undecanoate), "ignoring a petition submitted last week by a consumer group that...
Lipitor Down, But Not Out: Pfizer Plans an OTC Version. Will It Benefit or...
I've been following Lipitor's "demise" ever since Pfizer vowed the drug would maintain a 40% share of the total U.S. atorvastatin market.
In May 2012,...
The Virtual Sales Rep – It’s Not About eDetailing!
A growing number of doctors prefer digital communications and the pharmaceutical industry is currently in the process of moving its sales force to a smaller structure that is more directly aligned with this new reality. One aspect of that change is the deployment of
Right & Wrong Ways for Pharma to Correct Misinformation on Wikipedia
This article discusses both the right and wrongs ways for pharma to edit Wikipedia articles about its products using real-life examples.
Social Media, Latent Spokespersons & Native Advertising: Questions Raised by FDA Guidelines with Answers,...
This article focuses on a few of the issues, gray areas, and questions mentioned during the 'Green light or go slow' webcast and also in comments submitted to the FDA.
Pharma Marketing News Vol. 13, No. 3: March 2014
Welcome to Volume 13, Issue #3 (March 2014) of Pharma Marketing News.
